Back to Overview

Resilience Establishes Multi-Product Development And Manufacturing Collaboration With Takeda’s Plasma-Derived Therapies Business Unit

SAN DIEGO--(BUSINESS WIRE)--National Resilience, Inc. (Resilience), a technology-focused manufacturing company dedicated to broadening access to complex medicines, today announced a manufacturing services agreement with Takeda’s Plasma-Derived Therapies Business Unit.

Click here to read the full press release from Business Wire.

Resilience Announces Collaboration To Manufacture And Deliver Biotherapeutics For Rare And Complex Conditions

Collaboration includes build of embedded process and analytical development labs for use by Mayo Clinic and third-party...

Resilience Approved For $410M Financing From The Department Of Defense To Establish Resilient Biomanufacturing Capacity

Financing focused on domestic biomanufacturing capacity and capabilities for biologics, vaccines, and nucleic acids

Bluebird Bio And Resilience Announce Strategic Alliance To Develop Next Generation Cell Therapies

SAN DIEGO & BOSTON & CAMBRIDGE, Mass.--(BUSINESS WIRE)--National Resilience, Inc. (Resilience) and bluebird bio, Inc....

Resilience Establishes Multi-Product Development And Manufacturing Collaboration With Takeda’s Plasma-Derived Therapies Business Unit

Related Articles

Resilience Announces Collaboration To Manufacture And Deliver Biotherapeutics For Rare And Complex Conditions

Resilience Approved For $410M Financing From The Department Of Defense To Establish Resilient Biomanufacturing Capacity

Bluebird Bio And Resilience Announce Strategic Alliance To Develop Next Generation Cell Therapies